Dompé U.S. has agreed to pay $32 million to resolve allegations involving Medicare copay assistance for Oxervate, highlighting Anti-Kickback Statute compliance risks associated with manufacturer-funded patient assistance programs and the...
Dompé U.S. has agreed to pay $32 million to resolve allegations involving Medicare copay assistance for Oxervate, highlighting Anti-Kickback Statute compliance risks associated with manufacturer-funded patient assistance programs and the...
Florida has sued Express Scripts and Prime Therapeutics over allegations that the pharmacy benefit managers (PBMs) unlawfully coordinated pharmacy reimbursement rates, raising new antitrust and compliance questions surrounding PBM contracting...
Florida has sued Express Scripts and Prime Therapeutics over allegations that the pharmacy benefit managers (PBMs) unlawfully coordinated pharmacy reimbursement rates, raising new antitrust and compliance questions surrounding PBM contracting...
Walmart has agreed to pay $50 million to resolve federal allegations that its pharmacies unlawfully filled thousands of opioid and other controlled substance prescriptions.
Walmart has agreed to pay $50 million to resolve federal allegations that its pharmacies unlawfully filled thousands of opioid and other controlled substance prescriptions.
Monogram Health has agreed to pay $2.4 million to settle federal allegations that unsupported diagnosis codes led to increased Medicare Advantage payments.
Monogram Health has agreed to pay $2.4 million to settle federal allegations that unsupported diagnosis codes led to increased Medicare Advantage payments.
AstraZeneca has joined AbbVie and Novartis in challenging Illinois’ new 340B contract pharmacy law, adding to a growing national legal battle over state authority to regulate manufacturer distribution requirements and compliance data within...
AstraZeneca has joined AbbVie and Novartis in challenging Illinois’ new 340B contract pharmacy law, adding to a growing national legal battle over state authority to regulate manufacturer distribution requirements and compliance data within...
Eli Lilly has filed 6 lawsuits against companies allegedly selling unapproved versions of investigational obesity drug retatrutide, highlighting growing legal and regulatory scrutiny of unauthorized products entering the rapidly expanding...
Eli Lilly has filed 6 lawsuits against companies allegedly selling unapproved versions of investigational obesity drug retatrutide, highlighting growing legal and regulatory scrutiny of unauthorized products entering the rapidly expanding...
The Arkansas State Board of Pharmacy has suspended enforcement of a law restricting manufacturers' use of limited drug distribution networks after a federal court found the statute likely violates the dormant Commerce Clause, setting up a...
The Arkansas State Board of Pharmacy has suspended enforcement of a law restricting manufacturers' use of limited drug distribution networks after a federal court found the statute likely violates the dormant Commerce Clause, setting up a...
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
A Florida laboratory agreed to pay $9.8 million to resolve False Claims Act (FCA) allegations involving physician compensation arrangements that allegedly violated the Stark Law, highlighting ongoing federal scrutiny of referral-based...
A Florida laboratory agreed to pay $9.8 million to resolve False Claims Act (FCA) allegations involving physician compensation arrangements that allegedly violated the Stark Law, highlighting ongoing federal scrutiny of referral-based...
The Federal Trade Commission's (FTC) proposed settlement with CVS Caremark would require significant changes to pharmacy benefit manager (PBM) rebate practices, transparency, formulary management, and pharmacy contracting, signaling evolving...
The Federal Trade Commission's (FTC) proposed settlement with CVS Caremark would require significant changes to pharmacy benefit manager (PBM) rebate practices, transparency, formulary management, and pharmacy contracting, signaling evolving...
